Biotechnology companies can use "value-chain analysis" to create processes for maximizing the value of their intellectual property portfolios, say Bill Barrett and Dave Crawford.
No bricks, no mortar ... but lots of encouragement, introductions, good advice, and minimum conflicts of interest at the Massachusetts Institute of Technology, say Thomas Ittelson and Lita Nelsen.
